Blog

The latest thoughts from Medicines Law & Policy partners.

Generic versions of a lifesaving cystic fibrosis treatment will save patients $360,000 a year...

Generic versions of a cystic fibrosis treatment will now be available at $6,375 per child, per year under a new scheme – offering hope...

Socially Responsible Licensing of Medical Technologies

GENEVA, SWITZERLAND: On 31 October, the World Trade Organization (WTO), the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO) held their...

WIPO and pharma industry launch global medicines patent database

On 25 September, the World Intellectual Property Organisation (WIPO) in collaboration with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launched the Patent...

Dolutegravir Patent Licences Can Provide Access To All

This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential...

Humiragate: AbbVie’s desperate attempts to keep its monopoly

A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...

Trump Administration poses an unprecedented threat to life-saving health programmes 

On his first day in office, US President Trump issued several executive orders, one of which concerns US foreign aid. This order included a...

ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...

These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...

Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...

This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....

Modifier la législation européenne pour mettre en œuvre la licence d’office en France

Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. » L’augmentation croissante du prix...

Pharmaceutical Accountability Foundation meets AbbVie in court, looking to advance its pricing case

“The value of a human life is infinite, but unfortunately our healthcare budget is not,” said former Dutch Health Minister Bruno Bruins, quoted by...